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month	 postprocedurally,	 with	 additional	 bronchoprovocation	 at	 2‐year	 follow‐up.	
Airway	hyperresponsiveness	was	defined	as	≥20%	fall	of	forced	expiratory	volume	in	
1‐second	(FEV1)	following	<8.0	mg/mL	of	inhaled	methacholine.
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chest	 tightness	 and	 20%	 used	 bronchodilators.3	 Also,	 in	 a	 multi‐
center	population‐based	study	(unpublished	data),	use	of	pulmonary	
inhalants	was	found	to	be	twice	as	high	in	adult	ASD	patients	com‐




Among	 cardiac	 diseases,	 asthma‐like	 symptoms	 known	 as	 “car‐
diac	asthma”	are	extensively	described	in	patients	with	chronic	heart	
failure	with	or	without	mitral	 valve	disease,4‐9	 and	airway	hyperre‐
sponsiveness	 has	 been	 suggested	 to	 be	 the	 underlying	mechanism	
of	these	symptoms.	Airway	hyperresponsiveness	is	characterized	by	
more	sensitive	and	increased	airway	narrowing	to	nonspecific	stimuli	


















repeated	at	2‐year	postprocedural	 follow‐up	as	part	of	 this	 study.	
Additional	 cardiovascular	 magnetic	 resonance	 (CMR)	 imaging	was	
performed	at	the	physician’s	discretion.	The	study	cohort	comprised	
patients	 who	 had	 complete	 baseline	 pulmonary	 testing	 and	 who	





lines12	 and	 under	 general	 anesthesia	 for	 transesophageal	 echo‐
cardiographic	 guidance	 of	 device	 placement.	 Routinely,	 heparin	
and	 aspirin	 were	 administered	 at	 the	 start	 of	 the	 procedure	 and	
an	 Amplatzer	 Septal	 Occluder	 (Abbott	 Vascular	 BV,	 Santa	 Clara,	
California)	of	appropriate	size	was	 implanted.	Postprocedural	ther‐
apy	 included	 a	 6‐month	 dual	 antiplatelet	 regimen	 of	 daily	 aspirin	
100	mg	and	clopidogrel	75	mg	after	a	600‐mg	loading	dose.
2.3 | Methacholine challenge testing
Standardized	 spirometry	was	 performed	 on	 a	MasterScreen	 PFT	
(Jaeger,	 Wurzburg,	 Germany)	 and	 predicted	 values	 were	 based	
on	 age,	 sex,	 and	 height.13	 Bronchoprovocation	 testing	 was	 per‐
formed	according	to	the	2‐minute	tidal	breathing	method10,14	using	
a	 MasterScreen	 Body	 plethysmograph	 (Jaeger).	 Changes	 in	 air‐
way	caliber	were	expressed	as	forced	expiratory	volume	in	1	sec‐
ond	 (FEV1).	 After	 inhaling	 0.9%	 isotonic	 saline,	 patients	 received	
doubling	 doses	 of	methacholine	 chloride	 from	 0.6	 to	 1.2	mg/mL	
until	FEV1 decreased	≥20%	from	baseline	or	when	a	maximum	of	
19.6	mg/mL	methacholine	was	administered.	Airway	hyperrespon‐
siveness	was	defined	as	≥20%	of	FEV1 decline	 from	baseline	 fol‐
lowing	≤8.0	mg/mL	of	inhaled	methacholine.15	The	dose‐response	
curve	 served	 as	 quantitative	 index	 of	 airway	 responsiveness	 to	





As	 per	 clinical	 protocol,	 patients	 were	 excluded	 from	 bron‐
choprovocation	 testing	 if	 they	 had	 a	 myocardial	 infarction	
<3	months,	chronic	heart	disease	or	epilepsy	with	medical	therapy,	
were	 pregnant	 or	 breast‐feeding,	 or	 had	 FEV1 <70%	 of	 predicted.	




ing	 antimuscarinics	 <4	days,	 and	 the	 test	 was	 postponed	 in	 case	
of	respiratory	tract	 infections	<3	weeks.	To	minimize	confounding,	




The	 validated	 Dutch	 version	 of	 the	 European	 Community	
Respiratory	 Health	 Survey	 (ECRHS)	 was	 conducted	 before	 any	
spirometry,	enquiring	about	symptoms	of	wheezing	not	associated	
with	 the	 flu,	 (nocturnal)	 chest	 tightness,	 resting/exercise/noc‐
turnal	 dyspnea,	 (nocturnal)	 cough,	 and/or	 phlegm	 during	winter,	
troubled	 breathing,	 diagnosed	 asthma,	 nasal	 allergies,	 hay	 fever,	
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and	 eczema.17	 All	 questions	 refer	 to	 symptoms	 in	 the	 previous	
12	months	 or	 6	months,	 at	 baseline	 and	 follow‐up,	 respectively.	
Asthma	 definition	 and	 classification	 were	 based	 on	 the	 Global	
Initiative	for	Asthma	guidelines.11
2.5 | Imaging
Two‐dimensional	 echocardiography	 and	 CMR	 were	 performed	
at	 baseline	 and	 6‐month	 follow‐up	 as	 part	 of	 the	 outpatient	 vis‐
its.	 Echocardiographic	 views	 were	 acquired	 on	 a	 Vivid	 9	 (GE	
Healthcare,	 Horten,	 Norway)	 based	 on	 recommendations	 of	 the	











a	 phased‐array	 cardiac	 receiver	 coil.	 Functional	 imaging	 was	 per‐
formed	using	retrospectively	electrocardiographically	gated	steady‐
state	free	precession	cine	imaging	with	breath	holding.	Contiguous	
short‐axis	 slices	 were	 acquired,	 covering	 the	 entire	 left	 and	 right	
ventricle	from	base	to	apex,	to	examine	global	ventricular	function	
(typical	 scan	 parameters:	 slice	 thickness	 6	mm	with	 interslice	 gap	
3	mm,	matrix	 192	 x	 192,	 temporal	 resolution	 30‐55	ms,	 flip	 angle	
75°).	Analyses	of	right‐	and	left‐sided	end‐diastolic	and	end‐systolic	







Baseline	 characteristics,	 hemodynamics,	 and	 pulmonary	 function	




test	 where	 appropriate.	 The	 Friedman	 test	 was	 used	 to	 compare	
dose‐response	slopes	at	pre‐	and	6‐month	and	2‐year	post‐proce‐
dural	follow‐ups.	Differences	between	hyper‐and	normoresponsive	







airway	 responsiveness	 at	 6‐month	 and	 2‐year	 postprocedural	 fol‐
low‐up,	 and	 ventilatory	 and	 hemodynamic	 changes	 from	 baseline	
to	6	months	after	percutaneous	ASD	closure.	This	hypothesis‐gen‐
erating	study	did	not	allow	for	sample	size	specification.	Instead,	a	
post	 hoc	 power	 analysis	 was	 conducted	 using	 G*Power	 software	
(Heinrich‐Heine‐Universität	 Düsseldorf,	 Düsseldorf,	 Germany)	 set	
at	alpha	error	0.05	(one‐sided)	and	a	35%	prevalence	of	airway	hy‐
perresponsiveness	in	the	general	population.	A	power	of	≥80%	was	








spirometry	 and	 bronchoprovocation	 testing	 formed	 the	 study	 co‐
hort	(Figure	S1).
Baseline	 characteristics	 are	 shown	 in	 Table	 1.	 The	 mean	 age	
was	 49	±	15	years,	 65%	were	 female,	 and	 84%	were	 repaired	 for	
right	ventricular	dilatation	with	a	pulmonary‐to‐systemic‐flow	ratio	
of	 1.9	±	0.9.	 Based	 on	 the	Global	 Initiative	 for	 Asthma	 guidelines,	
4(13%)	patients	had	diagnosed	asthma	(n	=	2	mild,	n	=	2	moderate)	
and	11(35%)	patients	 had	 a	 self‐reported	history	of	 either	 allergic	











population.	 This	 yielded	 a	 post	 hoc	 statistical	 power	 of	 89%.	 The	
dose‐response	curve	of	all	individual	patients	is	shown	in	Figure	1A.
Figure	 1B	 shows	 the	 dose‐response	 slope	 at	 baseline	 and	 at	
6‐month	 and	 2‐year	 postprocedural	 follow‐up.	 At	 baseline,	 the	
hyperresponsive	 patients	 featured	 a	 dose‐response	 slope	 of	 2.87	










(8	 [42%]	vs.	1	 [9%];	P	=	.07).	 Irrespective	of	responsiveness	status,	
significant	 postprocedural	 improvement	was	 seen	 in	 symptoms	of	
troubled	 breathing	 and	 exertional	 dyspnea	 (both	 P	<	.001),	 while	
wheezing	and	chest	tightness	reduced	only	slightly	(Figure	2).
3.3 | Effect of closure




At	 baseline	 spirometry,	 FEV1 was	 3.0	±	0.9L/s	 (98%	±	15%	




P	=	.04),	 forced	 vital	 capacity	 (103%	±	16%‐108%	±	15%;	 P	<	.001)	
and	 inspiratory	 vital	 capacity	 (100%	±	16%‐103%	±	15%;	 P	=	.03).	
Low	baseline	 spirometry	values	were	associated	with	baseline	ex‐
ertional	dyspnea	(P	<	.01)	and	its	postprocedural	resolution	(P	≤	.01).
Following	 successful	 percutaneous	 closure,	 significant	 right	
atrial	and	ventricular	reverse	remodeling	was	observed.	CMR‐based	
right	ventricular	end‐diastolic	volume	decreased	from	134	±	40	mL/
m2‐96	±	23	mL/m2	 (P	<	.001),	 corresponding	 to	 right	 ventricular	










This	 study	 is	 the	 first	 to	 report	 a	 high	 prevalence	 of	 airway	 hy‐
perresponsiveness	 in	 a	 cohort	 of	 unrepaired	 adult	 ASD	 patients.	
Asthma‐like	 symptoms	 were	 more	 frequently	 reported	 in	 airway	
hyperresponsive	patients.	Parallel	to	the	unchanged	airway	respon‐
siveness	 after	 successful	 percutaneous	 ASD	 closure,	 asthma‐like	
symptoms	did	not	significantly	 improve	postclosure.	Regardless	of	
airway	 responsiveness,	 postprocedural	 right‐sided	 reverse	 remod‐
eling	significantly	improved	dyspnea	and	pulmonary	function.
4.1 | Airway hyperresponsiveness
Increased	airway	 responsiveness	 to	nonspecific	 stimuli	 is	one	of	
the	major	defining	features	of	asthma,	but	not	pathognomonic	for	
it.11	 In	the	general	adult	population	the	prevalence	of	airway	re‐
sponsiveness	 is	 10%‐16%	 (max.	 25%‐35%	as	 defined	by	 a	≤	10%	
FEV1	decline),
20,21	and	its	risk	factors	include	age,	female	gender,	
atopic	 constitution,	 respiratory	 tract	 infection,	 current	 smok‐
ing,	 and	 genetic	 predisposition.22	 The	 63%	 (95%CI	 45%‐81%)	




     |  5NASSIF et al.
prevalence	of	airway	hyperresponsiveness	in	this	study	is	signifi‐
cantly	 higher	 than	 expected	 from	 the	 prevalence	 in	 the	 general	
population	and	cannot	be	accounted	for	by	conventional	risk	fac‐
tors	 of	 hyperresponsiveness.	Only	 a	 few	 patients	 in	 this	 cohort	
were	current	smokers,	and	the	testing	season	had	no	influence	on	
airway	 responsiveness.	None	of	 the	 patients	 had	 comorbid	 lung	




respiratory	 disease,23	 no	 evidence	of	 such	medical	 reaction	was	
observed.




reporting	 unchanged	 airway	 hyperresponsiveness	 after	 treatment	
for	mitral	valve	disease,24‐26	although	some	improvement	in	airway	
sensitivity	was	seen.	A	previous	study	in	acute	on	chronic	heart	fail‐
ure	 patients	 also	 showed	 no	 alteration	 in	 responsiveness	 despite	
adequate	 diuretic	 therapy	 and	 significant	 radiological	 improve‐
ment.27	 Thus,	 pathophysiology	 inherent	 to	 such	 cardiac	 diseases	












after	 shunt	 repair	 (Figure	2).	Therefore,	 the	present	 study	confirms	
the	association	between	secundum	ASD	and	asthma‐like	symptoms,	













































6  |     NASSIF et al.
and	additionally	provides	data	that	suggests	that	airway	hyperrespon‐
siveness	is	one	of	the	possible	underlying	mechanisms.









sion	 by	 capillary	 recruitment.28	 Indeed,	 the	 observed	 significant	










smoke,	 and	 exercise	 may	 induce	 asthma‐like	 symptoms	 in	 ASD	
patients,	 regardless	of	 repair	status.	Unlike	 in	bronchial	asthma,11 
ASD‐associated	asthma‐like	symptoms	are	not	necessarily	episodic	
over	merely	few	hours	to	days,	but	can	manifest	with	progressive	
TA B L E  2  Ventilatory	and	hemodynamic	parameters	before	and	6	months	after	successful	ASD	closure
n Baseline Follow‐up Δ P value
Spirometry
Forced	expiratory	volume	in	1	s,	%pred 29 98	±	16 101	±	14 2.3	±	6.1 0.05
Forced	vital	capacity,	%pred 29 103	±	16 108	±	15 5.1	±	6.7 <0.001
FEV1/FVC	ratio,	%pred 29 100	±	8 98	±	9 −2.1	±	4.8 0.02
Peak	expiratory	flow,	%pred 29 105	±	22 108	±	21 2.9	±	11 0.15
Max.	expiratory	flow	at	50%	of	expiration,	
%pred
29 83	±	25 78	±	27 −4.3	±	16 0.16
Inspiratory	vital	capacity,	%pred 29 100	±	16 103	±	15 3.3	±	7.5 0.03
Maximal	vital	capacity,	%pred 29 101	±	16 106	±	14 4.6	±	7.1 0.002
Echocardiography
RA	end‐systolic	area,	cm2/m2 27 25	±	9.8 18	±	4.8 −7.0	±	7.6 <0.001
Tricuspid	annular	systolic	motion	velocity,	
cm/s
9 14	±	2.7 12	±	1.7 −1.3	±	2.2 0.11
Systolic	pulmonary	artery	pressure,	mm	Hg 23 34	±	7.8 27	±	4.5 −6.8	±	8.6 0.001
Pulmonary	capillary	wedge	pressure,	mm	Hg 25 n/a 13	±	2.7 n/a n/a
LA	end‐systolic	volume,	ml/m2 24 35	±	14 35	±	9.6 0.9	±	13 0.74
Cardiac	magnetic	resonance
RV	end‐diastolic	volume,	ml 21 249	±	83 182	±	62 −67	±	51 <0.001
RV	end‐diastolic	volume,	ml/m2 21 134	±	40 96	±	23 −38	±	30 <0.001
RV	end‐systolic	volume,	ml 21 104	±	41 83	±	34 −21	±	26 0.001
RV	end‐systolic	volume,	ml/m2 21 56	±	21 44	±	14 −13	±	16 0.002
RV	stroke	volume,	ml 21 145	±	47 101	±	30 −44	±	30 <0.001
RV	ejection	fraction,	% 21 59	±	6.1 56	±	5.6 −3.0	±	3.8 0.002
LV	end‐diastolic	volume,	mls 21 129	±	40 147	±	45 18	±	14 <0.001
LV	end‐diastolic	volume,	ml/m2 21 69	±	16 78	±	19 9.3	±	6.9 <0.001
LV	end‐systolic	volume,	ml 21 45	±	16 52	±	22 6.5	±	9.3 0.005
LV	end‐systolic	volume,	ml/m2 21 24	±	8 27	±	10 3.1	±	4.9 0.009
LV	stroke	volume,	ml 21 84	±	26 96	±	26 12	±	10 <0.001
LV	ejection	fraction,	% 21 65	±	5.5 66	±	6.5 0.4	±	5.3 0.72
LV	cardiac	output,	L/min 21 5.9	±	2.2 6.2	±	1.9 0.3	±	1.0 0.20
Data	are	presented	as	mean	±SD.	Abbreviations:	%Pred,	percentage	of	predicted	value;	FEV1,	forced	expiratory	volume	in	1	s;	FVC,	forced	vital	capac‐
ity;	RA,	right	atrial;	RV,	right	ventricular;	LA,	left	atrial;	LV,	left	ventricular.
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